Table of Contents
ISRN Pharmacology
Volume 2013, Article ID 546314, 7 pages
Research Article

N-Phenylpropyl-N′-(3-methoxyphenethyl)piperazine (YZ-185) Attenuates the Conditioned-Rewarding Properties of Cocaine in Mice

1Department of Psychological Sciences, 203 McAlester Hall, University of Missouri, Columbia, MO 65211, USA
2Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
3MU Research Reactor Center, University of Missouri, Columbia, MO 65212, USA
4Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 65201, USA
5Departments of Radiology, and Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
6Center for Translational Neuroscience, College of Medicine, University of Missouri, Columbia, MO 65211, USA

Received 12 July 2013; Accepted 7 August 2013

Academic Editors: R. Fantozzi and R. Villalobos-Molina

Copyright © 2013 Andrew S. Sage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Sigma receptor antagonists diminish the effects of cocaine in behavioral assays, including conditioned place preference. Previous locomotor activity experiments in mice determined that the sigma receptor ligand YZ-185 (N-phenylpropyl-N′-(3-methoxyphenethyl)piperazine) enhanced cocaine-induced hyperactivity at a lower (0.1 μmol/kg) dose and dose-dependently attenuated cocaine-induced hyperactivity at higher (3.16–31.6 μmol/kg) doses. The present study investigated the effect of YZ-185 on cocaine’s conditioned-rewarding properties in mice. YZ-185 (0.1, 0.316, 3.16, and 31.6 μmol/kg) did not have intrinsic activity to produce conditioned place preference or aversion. A higher (31.6 μmol/kg) YZ-185 dose, but not lower (0.1–3.16 μmol/kg) YZ-185 doses, prevented the development of place preference to cocaine (66 μmol/kg). YZ-185 did not alter the expression of cocaine place preference. To further characterize YZ-185’s behavioral profile, its effects in the elevated zero maze and rotarod procedures were also determined; YZ-185 produced no significant change from baseline in either assay, indicating that the sigma receptors probed by YZ-185 do not regulate anxiety-like or coordinated motor skill behaviors. Overall, these results suggest that YZ-185 is a sigma receptor antagonist at the 31.6 μmol/kg dose and demonstrate that sigma receptors can mediate the development of the conditioned-rewarding properties of cocaine.